| Name | Title | Contact Details |
|---|
Rhapsody partners with healthcare organizations around the globe delivering its adaptable Interoperability Suite to reliably connect, classify, and clean data. Rhapsody health solutions power the applications and workflows that improve clinical, operational, and financial outcomes today while helping teams respond to and prepare for changes on the horizon. Rhapsody is committed to empowering people throughout the healthcare ecosystem, from specialty clinics to large care networks, from public health to health technology, and everything in between.
American Clinical Solutions is a leading provider of urine drug confirmation services, offering accurate testing for both prescription and illicit narcotics using the most advanced equipment available. Medical facilities and other healthcare providers rely on American Clinical to help ensure patient safety and maximize the benefits of prescription medicine use. ACS employs a unique, proprietary testing method with enhanced detection ability and improved accuracy which means physicians and other health care providers can prescribe with confidence. In addition to detecting improper use of prescribed and illicit drugs, ACS testing method helps healthcare providers monitor the efficacy of prescription regimens and alter the dosing scheme in response to changes in patient health status, behavior or other variables, helping patients achieve better outcomes while providing an overall greater level of safety. ACS techniques and technology were developed to meet or exceed the latest testing standards. Input from our physician colleagues provides invaluable guidance to help us refine our approach to ensure we continue to provide the best, most accurate testing results and reporting services available.
Quip is the oral care company designing and delivering products, advice and professional services to make oral health more simple, accessible, and enjoyable.
CrescentCare is an organization of health and wellness centers that is responding to the need for broader healthcare services in the Greater New Orleans area. CrescentCare uses proven interventions and evidence-based practices to improve outcomes for i...
Aimmune is a clinical-stage biopharmaceutical company advancing a new therapeutic approach, including the development of proprietary product candidates, for the treatment of peanut and other food allergies. Our mission is to improve the lives of people with food allergies by developing and commercializing proprietary desensitization therapies that safely and reliably protect them from accidental exposure to food allergens. We aim to address food allergies by providing a treatment option that goes beyond the current protocols of avoiding exposure to food allergens and carrying epinephrine for administration in case of accidental exposure. Our CODIT™ system is based on extensive independent scientific research demonstrating that most patients with food allergies can become desensitized to the allergens, or proteins, in a particular food through the oral administration of gradually increasing amounts of the allergens. In oral immunotherapy (OIT), a very small amount of an allergen is administered on a daily basis and then regularly increased until desensitization to a certain amount of the allergen has been achieved. We plan to develop and commercialize standardized, pharmaceutical-grade food allergens for our CODIT™ (characterized oral desensitization immunotherapy) system, our system for OIT. Our lead product candidate, AR101, is a standardized, complex mixture of 13 naturally occurring proteins and pharmaceutical-grade ingredients that, with the CODIT system of gradual, controlled updosing and ongoing maintenance dosing, has obtained meaningful desensitization to peanut allergens in our initial clinical studies.